Eli Lilly and Company (LLY)
| Market Cap | 720.73B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 52.50 |
| Forward PE | 29.21 |
| Dividend | $6.00 (0.75%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 3,934,951 |
| Open | 788.96 |
| Previous Close | 819.38 |
| Day's Range | 783.85 - 804.44 |
| 52-Week Range | 623.78 - 935.63 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 969.56 (+20.77%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $969.56, which is an increase of 20.77% from the latest price.
News
Our Top 10 High Growth Dividend Stocks - October 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
President Trump targets $150 MFN price for GLP-1s
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1...
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th...
3 Price Catalysts For Eli Lilly
Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or...
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Li...
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the P...
Eli Lilly, Novo Nordisk Stocks Drop After Trump's Ozempic Price Comment. What to Know.
Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”
Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower
Stock index futures decline as regional bank health worries weigh on sentiment, with S&P 500, Nasdaq 100, and Dow futures all in the red. Novo Nordisk (NVO) and Eli Lilly (LLY) shares drop after Trump...
Lilly confirms date and conference call for third-quarter 2025 financial results announcement
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call tha...
Eli Lilly: Outstanding Orforglipron Data Reinforces Value Proposition
Eli Lilly and Company reported strong Phase 3 results for its oral GLP-1 drug orforglipron in type 2 diabetes, meeting all primary and secondary endpoints. LLY's GLP-1 franchise, including Mounjaro, Z...
How LLY Stock Delivered $47 Billion To Shareholders
In the last decade, Eli Lilly stock (NYSE: LLY) has returned $47 billion to its shareholders via dividends and buybacks. This shareholder-centric approach has delivered solid results in 2025, with the...
Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials
Eli Lilly said on Wednesday its oral drug, orforglipron, helped reduce blood sugar levels in two late-stage trials.
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insu...
Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice
Papa John's (PZZA) surged nearly 10% after reports of a $64/share takeover bid from Apollo Global. PZZA is up 3% premarket.
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade)
Eli Lilly stock has recovered resoundingly, outperforming the S&P 500, Novo Nordisk, and healthcare peers after a period of decline. LLY's robust pipeline, expansion into cardiometabolic and oncology ...
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powe...
Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral presentati...
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa
South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes and obesity drug, Mounjaro, for chronic weight management in the country.
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices ...
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Eli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price.
HealthTap joins Lilly's online platform to offer diabetes management services
Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's digital healthcare platform, LillyDirect, to offer virtual diabetes management services.
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday.
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years,...